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Abstract: Food fortification programs to reduce iron deficiency anemia require bioavailable forms
of iron that do not cause adverse organoleptic effects. Rodent studies show that nano-sized
ferric phosphate (NP-FePO4) is as bioavailable as ferrous sulfate, but there is controversy over
the mechanism of absorption. We undertook in vitro studies to examine this using a Caco-2 cell
model and simulated gastrointestinal (GI) digestion. Supernatant iron concentrations increased
inversely with pH, and iron uptake into Caco-2 cells was 2–3 fold higher when NP-FePO4 was
digested at pH 1 compared to pH 2. The size and distribution of NP-FePO4 particles during GI
digestion was examined using transmission electron microscopy. The d50 of the particle distribution
was 413 nm. Using disc centrifugal sedimentation, a high degree of agglomeration in NP-FePO4
following simulated GI digestion was observed, with only 20% of the particles ≤1000 nm. In Caco-2
cells, divalent metal transporter-1 (DMT1) and endocytosis inhibitors demonstrated that NP-FePO4
was mainly absorbed via DMT1. Small particles may be absorbed by clathrin-mediated endocytosis
and micropinocytosis. These findings should be considered when assessing the potential of iron
nanoparticles for food fortification.
Keywords: nano iron; NP-FePO4; bioavailability; Caco-2 cells; simulated gastrointestinal digestion;
DMT1; endocytosis
1. Introduction
Iron deficiency is the most prevalent nutritional deficiency in the world, affecting 1–2 billion
people worldwide [1]. Food fortification is an effective strategy to reduce the burden of iron deficiency
in populations [2,3]. Iron salts, iron chelates, and elemental powders are all iron sources approved
for food fortification [3], but each form has inherent disadvantages. Soluble iron compounds, such as
ferrous sulfate (FeSO4) and ferrous gluconate, have high iron bioavailability but may cause adverse
organoleptic changes when added to foods. Insoluble iron compounds, such as electrolytic iron and
ferric phosphate (FePO4), are stable in foods but have low iron bioavailability [4–6]. FePO4 is an iron
compound that causes no adverse organoleptic changes in food matrices, but is poorly absorbed (25%)
relative to FeSO4 [4], therefore its nutritional value is limited.
The bioavailability of elemental iron powders has been shown to be inversely related to particle
size. Harrison et al. [7] found that decreasing the particle size of FePO4 from 12–15 µm to 1 µm
increased iron solubility and improved relative biological value (RBV) 5-fold. Decreasing particle size
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to the nanoscale could be a strategy to improve iron bioavailability. Recently, FePO4 synthesized to the
nanoscale (NP-FePO4) by flame spray pyrolysis (FSP) was reported to have similar iron bioavailability
to FeSO4 in rat models [8]. This has been attibuted to its increased solubility as a result of higher
surface area relative to its larger precursors. However, further studies are required to confirm that the
findings in rats can be extrapolated to humans [9] given that rodents endogenously synthesize ascorbic
acid [10] and are less affected by dietary inhibitors of iron absorption than humans [11]. In the present
study, we examined the effects of in vitro simulated gastrointestinal digestion on the size distribution
of NP-FePO4, supernatant iron, uptake into Caco-2 cells, and mechanisms of absorption.
2. Materials and Methods
Samples of NP-FePO4, previously characterized for crystalline structure, phase distribution,
chemical composition, and specific surface areas (SSA, 100 and 200 m2/g) [8,12], were kindly donated
by ETH Zurich.
2.1. NP-FePO4 Treatments: Sonication
NP-FePO4 was diluted to a concentration of 1 mg/mL either in water or minimum essential
media (MEM). The suspensions were probe sonicated for 15 min (MSE Soniprep 150 Plus, London, UK)
on maximum setting (Amplitude: 16.1 A, 150 W).
2.2. NP-FePO4 Treatments: In Vitro Simulated Gastrointestinal (GI) Digestion
NP-FePO4 was exposed to in vitro simulated gastrointestinal digestion [13–15]. Briefly, 10 mL
40 mM NaCl and 5 mM KCl pH 2 solution containing 0.4% pepsin was added to NP-FePO4 in a 50 mL
polypropylene tube. The mixture was placed on a rotating table (100 rpm) and incubated for 1 h at
37 ◦C. After 1 h, the pH of the digests was readjusted to 5.5–6.0 and a pancreatin-bile solution (0.25%)
added. The pH was further adjusted to 6.9–7.0 with 1 M NaHCO3 and incubated for a further 30 min
at 37 ◦C.
2.3. Transmission Electron Microscopy (TEM)
TEM micrographs were generated for visualization of NP-FePO4 (200) during in vitro digestion.
During each digestion phase, an aliquot of digested NP-FePO4 (200) was drop spotted onto
carbon-coated copper TEM mesh grids and dried for 1 h. TEM mesh grids were washed 5 times
with milliQ H2O and subsequently air-dried for 24 h. Particles were visualized using a Jeol 1200EX
electron microscope (JEOL, Tokyo, Japan) operated at 80 kV.
2.4. Centrifugal Disc Sedimentation
A CPS disc centrifuge model 2400 (CPS Instruments, Oosterhout, UK) was used to measure
the total particle distribution given the heterogeneity, polydispersity, and aggregated/agglomerated
particle patterns during in vitro digestion. The instrument was run at 5000 rpm (20 ◦C) for 30 min.
A sucrose gradient was established using two sucrose solutions (24% and 8% w/v). After setting of
the gradient, the instrument was calibrated to polystyrene standards (0.239 µm) followed by sample
(100 µL).
2.5. Dynamic Light Scattering (DLS)
Hydrodynamic particle size of NP-FePO4 in cell culture media was measured using dynamic
light scattering (DLS) with the Zetasizer Nano-ZS (Malvern Instruments, Malvern, UK). Particles
(1 mg/mL in MEM) were sonicated and analysed immediately. The refractive index of the material
was considered as 1.68. Intensity-based particle sizes were converted and are reported as volume
based [16].
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2.6. Caco-2 Cell Culture
Caco-2 cells (HTB-37® VA) from the American Type Culture Collection were grown in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 1% non-essential amino
acid solution, 1% penicillin/streptomycin, and 1% L-glutamine. Cells were grown in 75 cm2 cell
culture flasks (Greiner, UK) and incubated in 5% carbon dioxide/95% air atmosphere at constant
humidity. The media was replaced every 2–3 days. For iron uptake experiments, cells were seeded onto
collagen-coated 6- or 12-well plates and grown for 12 days. After 12 days, cells were placed in MEM
containing 19.4 mM D-glucose, 26.2 mM NaHCO3, 10 mM PIPES (piperazine-N,N-bis-(2-ethanesulfonic
acid)), 1% antibiotic-antimycotic solution, 4 mg/L hydrocortisone, 5 mg/L insulin, 0.02 µM Na2SeO3,
0.05 µM triiodothyronine and 0.2 mg epidermal growth factor for 24 h prior to iron treatments.
Experiments were conducted using cell passages 25–40.
2.7. Supernatant Iron during In Vitro Gastric Digestion
Supernatant iron from NP-FePO4 (soluble and <100 nm fractions) was quantified after iron
dissolution at low pH [12,17]. Supernatant iron was measured with respect to time and pH at the end
of the gastric phase. At each time point, 1 mL aliquots were removed from digestion and centrifuged
immediately for 5 min at 11,600× g. The supernatant was removed and analyzed for iron content
against a non-centrifuged control (total iron). The iron content of samples was determined using the
iron chelator, 3-(2-pyridyl)-5,6-bis(5-sulfo-2-furyl)-1,2,4-triazine, disodium salt trihydrate (Ferene-S,
Sigma, Gillingham, UK) with ammonium iron (II) sulfate as the iron standard curve. Briefly, 100 µL
sample was diluted in 100 µL 1% HCl and incubated at 80 ◦C for 10 min. Samples were cooled
on ice, followed by sequential addition of 500 µL 7.5% ammonium acetate, 100 µL 2.5% sodium
dodecylsulphate, 100 µL 4% w/v ascorbic acid, and 100 µL 1.5% ferene. Samples were read at 593 nm.
2.8. Measurement of Iron Uptake into Caco-2 Cells
Iron uptake into Caco-2 monolayers was determined using cell ferritin formation (ng cell
ferritin/mg cell protein). In each cell culture experiment, ferric ammonium citrate (FAC) was included
as a control. FAC is a well-absorbed form of iron in Caco-2 cells and used as the reference for DMT1
uptake [18–20]. Reference blanks (cells not treated with iron) were included in each experiment to
ensure low baseline levels of cell ferritin. After iron treatment, cells were washed twice with PBS and
lysed with 200 µL CelLytic M protein lysis buffer (Sigma). Lysed cells were centrifuged (14,000× g,
15 min), supernatants collected, and analyzed for cell ferritin using the Spectroferritin ELISA kit (ATI
Atlas, Chichester, UK). Cell ferritin was normalized to total protein concentrations using the BCA
protein assay kit (ThermoFisher Scientific, Loughborough, UK).
2.9. Chemical Inhibitors Targeting Iron Uptake
All chemicals, unless otherwise stated, were from Sigma and used at the following concentrations.
For in vitro simulated GI digestion experiments, ascorbic acid (AA) (1:20 Fe:AA molar ratio, 600 µM)
was added at the beginning of the gastric phase as an enhancer of non-haem iron bioavailability. 2.5 mM
CaCl2 (after dilution with digests) was added directly in MEM and used as an inhibitor of non-heme
iron bioavailability. In both conditions, digests were incubated with cells for 24 h. For sonicated
NP-FePO4 (200), clathrin-mediated endocytosis was inhibited using chlorpromazine hydrochloride
(100 µM) and sucrose (0.5 M). Clathrin-independent endocytosis targeting caveolae-mediated
endocytosis and macropinocytosis were inhibited with filipin (5 mg/L) and dimethyl amiloride (DMA,
200 µM), respectively [21–26]. Caco-2 cells were co-incubated with iron treatment and endocytosis
inhibitors for 1 h, removed, and incubated for a further 23 h.
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2.10. siRNA Knockdown of DMT1 in Intestinal Epithelial Cells
Caco-2 cells, seeded into 12-well collagen-coated plates (200,000 cells/well), were grown for
10 days. Transient knockdown of DMT1 was initiated according to the method of Latunde-Dada et al.
2014 [27]. Cell monolayers were transfected with Silencer® Select siRNA targeting SLC11A2 (the gene
encoding DMT1) or Negative control no. 1 (200 nM, Life Technologies) using Lipofectamine 3000
in Opti-MEM (Gibco) for 48 h. After 48 h, siRNA complexes were replaced with FAC or NP-FePO4
(200) for 2 h. Iron treatments were removed, MEM added, and cells were incubated for a further
22 h. Wells in parallel with the same treatments were used to analyze for cell ferritin/protein and
RNA extraction prior to RT-PCR. For Hutu-80 cells, 12-well plates (100,000 cells/well) were grown
until 50%–70% confluent. Cell monolayers were transfected with Silencer® Select siRNA targeting
SLC11A2 or Negative control no. 1 (10 nM) in Opti-MEM for 48 hours. Iron treatments and incubations
paralleled the siRNA knockdown experiments undertaken in Caco-2 cells. Cell ferritin formation was
normalised to FAC for siRNA experiments.
2.11. RT-PCR
The RNeasy Mini Kit (Qiagen, Hilden, Germany) was used for RNA extraction according
to manufacturer’s instructions. RNA quality was determined using UV-Vis Nanodrop 2000
spectrophotometer (ThermoFisher Scientific, Loughborough, UK). Complementary DNA (cDNA)
was synthesized using the qPCRBIO cDNA Synthesis Kit (PCR Biosystems, London, UK). 0.1 mg
RNA was reverse transcribed to cDNA. Predesigned primers (KiCqStart SYBR Green Primers, Sigma,
Gillingham, UK): SLC11A2, Forward: GAG TAT GTT ACA GTG AAA CCC; Reverse: GAC TTG ACT
AAG GCA GAA TG; 18S, Forward: ATC GGG GAT TGC AAT TAT TC; Reverse: CTC ACT AAA CCA
TCC AAT CG. Real time PCR proceeded with 4 µL cDNA and 2× SYBR Green Mix Lo-ROX (PCR
Biosystems) and run using the Roche Lightcycler 480 (Roche, Burgess Hill, UK). Relative expression
of SLC11A2 (DMT1) was normalised to the housekeeping gene 18S, and assessed using the ∆∆Ct
method [28].
2.12. Statistical Analysis
Statistical analysis was performed using GraphPad Prism v.6.0 (San Diego, CA, USA). Particle
size was calculated using Feret’s diameter and particle size distributions expressed using the median
particle size (d50) with d10 representing 10% and d90 representing 90% of the particle sizes. One-way
repeated measures ANOVA with Tukey’s multiple comparisons test was used to compare differences
in iron uptake or one-way repeated measures ANOVA with Dunnett’s test were used to compare
differences between NP-FePO4 (200) and NP-FePO4 (200) treated with chemical inhibitors. Cell
culture experiments were repeated 2–3 times, with n = 3 per experiment. Differences were considered
significant at p < 0.05.
3. Results
3.1. Particle Size
3.1.1. Characterization of Sonicated NP-FePO4
Sonicated NP-FePO4 (200) and NP-FePO4 (100) particle sizes were characterized in MEM using
DLS. Sonicated NP-FePO4 (200) hydrodynamic diameter averaged 341 nm (d10, d90: 190, 459) and
NP-FePO4 (100), 458 nm (d10, d90: 342, 532) (Figure 1A,B). Visual morphology of NP-FePO4 (200)
comparing diluted (non-sonicated) or dispersed (sonicated) particles was conducted using TEM with
water as the diluent. Large, agglomerated, electron dense particles formed without sonication in the
micron range (Figure 1C) with d50 = 1990 nm (Figure 2B). Sonication of NP-FePO4 (200) resulted in
particle dispersal of similar size to the acquired DLS data (Figure 1D); d50 = 312 nm.
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Figure 1. Size determination of sonicated nano-sized ferric phosphate (NP-FePO4). 1 mg/mL NP-
FePO4 dispersions in minimum essential media (MEM) were measured using dynamic light 
scattering, n = 3 (A,B). 1 mg/mL NP-FePO4 (200) directly diluted in H2O (unsonicated) (C) or dispersed 
by sonication and visualized using transmission electron microscopy (TEM) (D). SSA, specific surface 
areas; MPS, mean particle size. 
 
Figure 2. Size determination of NP-FePO4 (200) during different stages of in vitro digestion. 1 mg/mL 
stock solutions in water were diluted to 30 µg/mL in digestion solutions, and visualised using TEM. 
Particle sizes were calculated using ImageJ software analysis (A) and particle size distributions 
reflected in the table (B). Representative TEM micrographs used in the analysis of size and size 
distributions at pH 2, t = 0 min (C), pH 2, t = 60 min (D), and pH 7, t = 30 min (E). Histogram of particle 
distribution based upon total particle population during stages of in vitro digestion (F).  
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3.1.2. In Vitro Simulated GI Digested NP-FePO4 (200)
Particle size of NP-FePO4 (200) during in vitro digestion was visualized using TEM and particle
size analysis with ImageJ software. Non-digested particles agglomerated in water as previously shown,
resulting in d50 = 1996 nm. The particle size shifted to d50 = 771 nm after exposure to initial gastric
digestion (pH 2). 60 min exposure in pH 2 caused further reduction of particle size to d50 = 348 nm.
The particle size slightly agglomerated to d50 = 413 nm after the in vitro digest was neutralized (pH 7,
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t = 30) with 0.1 M NaHCO3 (Figure 2A,B). Total particle population size distibutions during in vitro
digestion were conducted using CPS (Figure 2F). After 60 min digestion at pH 2, 50% of the particle
sizes were ≤1000 nm, and 30% of the particles were ≤400 nm. At pH 7, rapid agglomeration of the
particles led to an 80% increase in micron-sized fractions, and the proportions of the 100–400 nm and
400–1000 nm fractions were reduced to <10%. Overall, about 15% of the particles were ≤400 nm after
in vitro digestion.
3.2. Cell Culture Experiments
3.2.1. Effect of Gastric pH and Time on Supernatant Iron and Uptake into Caco-2 Cells
The effects of time of exposure and pH on supernatant iron concentration and uptake were
compared using Caco-2 cells. At pH 2, NP-FePO4 (100 and 200) was digested for 30, 60, and 120 min and
aliquots were taken to determine supernatant iron. The remaining digestion solution was neutralized
at pH 7 and incubated for a further 30 min for cellular iron uptake. Supernatant iron increased with
longer gastric digestion times, but no significant difference was observed between the two particle
sizes. Compared to FAC, NP-FePO4 supernatant iron reached 70% after 2 h digestion (Figure 3A). Iron
uptake was significantly increased when NP-FePO4 was digested for 120 min compared to 30 min
for both particle sizes but only half as absorbed compared to FAC (Figure 3C). In contrast, the pH of
the gastric digest had a large effect on supernatant iron and uptake of iron from NP-FePO4. Iron was
completely in the supernatant fraction when NP-FePO4 was digested at pH 1, whereas 5%–10% of iron
was in the supernatant at pH 4 for both particles (Figure 3B). NP-FePO4 was not taken up (compared to
controls not containing iron) after digesting both particles at pH 4 for 1 h. Iron uptake from NP-FePO4
(200) was significantly increased relative to NP-FePO4 (100) when digested at pH 1 and similar to FAC
(Figure 3D).
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Figure 3. Effect of gastric digestion on supernatant iron and iron uptake in Caco-2 cells. Ferric
ammonium citrate (FAC) or NP-FePO4 (30 µM Fe) was digested at pH 2 for varying times (A) or
digested at varying pH for 1 hour (B) and supernatant iron determined at the end of gastric digestion.
Caco-2 cells were exposed to digested FAC or NP-FePO4 (30 µM Fe) for 24 h and measured for cell
ferritin formation (C,D). Data values are expressed as the means of two independent experiments (n = 3
per experiment, ± standard error of the mean (SEM)). One-way repeated measures analysis of variance
(ANOVA) with Tukey’s multiple comparisons test was used to compare differences in iron uptake
between iron treatment (FAC or NP-FePO4) with time or pH. Different letters indicate statistically
significant differences (p < 0.05).
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3.2.2. Effect of AA and Calcium on Iron Uptake in Caco-2 Cells
NP-FePO4 was digested using standard in vitro gastrointestinal conditions. Particles were
digested at pH 2 for 1 h and pH 7 for 30 min. Ascorbic acid added to the digest (1:20 AA molar
ratio) during the gastric phase increased iron uptake of FAC 2-fold and both forms of NP-FePO4
3–4 fold. The increase in iron uptake of NP-FePO4 with added AA was similar to FAC and FAC
with AA (Figure 4A), correlating with increased supernatant iron of NP-FePO4 with AA at neutral
pH (Supplementary Figure S1). NP-FePO4 was digested and added to MEM containing a final
concentration of 2.5 mM CaCl2 after dilution (Figure 4B). Calcium (as CaCl2) inhibited iron uptake
from FAC and NP-FePO4 (200) by 50%. Iron uptake of NP-FePO4 (100) was marginally decreased with
CaCl2 but the effect was not statistically significant, which might be due to the low basal levels of iron
uptake observed (Figure 4B).
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Figure 4. Iron uptake of in vitro simulated GI digested FAC or NP-FePO4 after incubation with ascorbic
acid (1:20 AA molar ratio) introduced at the gastric phase or CaCl2 (2.5 mM, final volume in MEM
after dilution) in C co-2 cells after 24 h. Caco-2 cells were exposed to digested FAC or NP-FePO4
(30 µM Fe) and incubated with ascorbic acid (A) or CaCl2 in MEM (B) for 24 h and measured for cell
ferritin formation. Data values are expressed as the means of two independent experiments (n = 3 per
experiment,± SEM). One-way repeated measures ANOVA with Tukey’s multiple comparisons test was
used to compare differences in iron uptake between iron treatment (FAC or NP-FePO4) with enhancer
(AA) or inhibitor (CaCl2). Different letters indicate statistically significant differences (p < 0.05).
Using sonicated NP-FePO4 (200), CaCl2 did not inhibit iron uptake. Iron uptake was significantly
reduced when sonicated particles were incubated in the presence of chlorpromazine, sucrose, and
DMA (Figure 5).
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Figure 5. Iron uptake of sonicated NP-FePO4 (200) co-incubated with chemical inhibitors targeting
endocytosis uptake pathways in Caco-2 cells as measured by cell ferritin formation. NP-FePO4 (200)
(100 µM Fe) was incubated directly in MEM with inhibitors and placed onto Caco-2 cells for 1 h. Cells
were washed 3× with PBS and replaced with MEM for a further 23 h. Data values are expressed
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measures ANOVA with Dunnett’s multiple comparison test was used to distinguish differences in iron
uptake between control (NP-FePO4 (200)) and NP-FePO4 (200) co-incubated with chemical inhibitors.
Asterisks indicate statistically significant differences from control (p < 0.05).
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3.2.3. Effect of siRNA-Mediated Knockdown of DMT1 in Caco-2 and Hutu-80 Cells
Under our experimental conditions, DMT1 expression was reduced by 20% in Caco-2 cells
following exposure to SLC11A2 siRNA (Figure 6A). The reduction in DMT1 expression was sufficient
to significantly reduce iron uptake from FAC by 20%. Iron uptake from sonicated NP-FePO4 (200) was
not different in siRNA DMT1 treated cells (Figure 6B) relative to control cells. However, uptake from
digested NP-FePO4 (200) was decreased in DMT1-knockdown cells (Figure 6C).
The Hutu-80 cell line was used to validate DMT1 knockdown of Caco-2 cells, since its transfection
efficiency is improved in comparison to Caco-2 cells. DMT1 expression was reduced by 50% in Hutu-80
cells. In both digested and sonicated NP-FePO4 (200), DMT1 knockdown resulted in significant
inhibition of iron uptake by 40%–50% (Figure 6C,D). In both cell lines, DMT1 expression from negative
control siRNA was not different than from control cells without siRNA.
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Figure 6. Iron uptake of sonicated and in vitro digested P-FeP (200) or F in non-targeting
siR (negative control 1) or SLC11A2 siRNA treated Caco-2 cells (A,B) or Hutu-80 cells (C,D)
after 2 h exposure followed by incubation in MEM for a further 22 h. Cell ferritin formation was
normalized relative to FAC treatments. Data values are expressed as the means of three independent
experiments (n = 3 per experiment, ± SEM). One-way repeated measures ANOVA with Tukey’s
multiple comparisons test was used to compare differences in iron uptake between iron treatment (FAC
or NP-FePO4 [200]) in non-targeting siRNA or SLC11A2 siRNA treated cells. Different letters indicate
statistically significant differences (p < 0.05).
4. Discussion
Food iron fortification is technically challenging as the fortificant cannot react with food matrices.
The elemental powders H-reduced, carbonyl, electrolytic iron, FePO4, and ferric orthophosphate do
not react with food matrices and are widely used. However, low iron bioavailability of elemental
powders relative to water-soluble compounds limit their nutritional value. Particle size reduction
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is an effective strategy for improving iron bioavailability from elemental powders [29]. Particle size
reduction is inversely related to iron solubility at low pH, which has been shown to be the best in vitro
predictor of iron bioavailability in humans [17,30]. The advent of nanotechnology has facilitated the
synthesis of “micro” and “nano” sized particles with defined size and morphology. Recent studies
have demonstrated good iron bioavailability of micronized ferric pyrophosphate (SunActive© Fe,
Yokkaichi Japan), with estimated mean particle size of 0.3 µm, in humans [31–34]. The bioavailability
of NP-FePO4 has been shown to be effective as ferrous sulfate in rats using the hemoglobin repletion
assay [8,12]. The present study aimed to elucidate the mechanisms involved in iron uptake from
NP-FePO4 using cellular models.
We investigated two separate mechanisms of iron uptake into Caco-2 cells; iron uptake via DMT1,
and direct endocytosis of NP-FePO4. We first characterised NP-FePO4 in solution. Nanoparticle
toxicity is a concern since small particle size is a factor that can lead to enhanced rates of translocation
into body tissues. With increasing interest in using iron nanoparticles as food fortificants, it is possible
that non-homeostatically regulated iron uptake may occur, resulting in oxidative stress. An assessment
of the toxicity of specific particles includes consideration of particle size, dispersity, agglomeration state,
surface characteristics, charge, and cell type, as each parameter is an important factor determining
nanoparticle uptake [35–38].
In addressing exposure of Caco-2 cells to NP-FePO4, we modelled the size distribution of particles
during a physiologically relevant exposure using a validated in vitro method [13,39]. This method
estimates iron bioavailability from an in vitro simulated GI digestion/Caco-2 cell model and has
shown to correlate well with data from human trials [40,41]. Using disc centrifugal sedimentation
(DCS), the majority of particles agglomerated when NP-FePO4 (200) was exposed to simulated
in vitro digestion. Agglomerated particle fractions suggest limited toxicity of NP-FePO4 (200) to
the intestinal epithelium with respect to its smaller (dried) precursors [11,21,27]. Agglomeration of
particles was not observed using TEM, which is likely due to technical differences in microscopy and
laser diffraction [28].
Next we examined the effects of gastric digestion on iron uptake of NP-FePO4 in Caco-2 cells.
We use the term supernatant iron throughout, rather than soluble iron, as it accurately describes the
nature of the aqueous phase containing a combination of soluble iron and nanoparticles <100 nm after
centrifugation when 3 kDa molecular weight cut off (MWCO) spin filters are omitted [16,26]. Cell
ferritin formation served as the surrogate marker of iron absorption [8,33]. Gastric digestion at pH 1
for 1 h significantly increased supernatant iron and iron uptake compared to pH 2 and pH 4. Gastric
digestion at pH 2 for 30 min, 60 min, and 120 min led to increases in supernatant iron and uptake
with time, but the effect of time was much less pronounced than pH. Coupling gastric digestion at
pH 1 to Caco-2 cells resulted in more bioavailable iron from NP-FePO4 (200) compared to NP-FePO4
(100). Iron uptake of NP-FePO4 (200) was similar to FAC. Rohner et al. [6] and Hilty et al. [7] observed
similar iron uptake of NP-FePO4 (200) compared to FeSO4 in rats and suggested that its high iron
uptake is a result of increased iron particle dissolution compared to commonly used FePO4.
While iron bioavailability of foods and the effects of dietary factors using the in vitro
digestion/Caco-2 cell model has been shown to correlate well with human absorption data [40,41],
the usefulness of the model for elemental iron powders as a predictor for human bioavailability has
been questioned [5,42]. Breads fortified with 8 micron sized H-reduced iron were more bioavailable
than breads fortified with 45 micron sized H-reduced iron in Caco-2 cells, and a linear relationship was
found between solubility and iron bioavailability [43]. Similarly, 40–60 nm H-reduced iron particles
were more bioavailable compared to its larger precursors [44]. Others have found that the Caco-2
cell model cannot consistently predict the bioavailability of iron fortificants within food matrices that
have been observed in humans [45,46]. Forbes et al. compared two iron fortificants, electrolytic iron
and ferric orthophosphate, with FeSO4 using in vitro solubility at pH 1.2 and absorption studies in
humans [4]. The compounds were ranked in the same order (ferrous sulfate > electrolytic iron > ferric
orthophosphate), although the solubility test underestimated the relative biological value of ferric
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orthophosphate. They concluded that these results, together with those from earlier studies, suggested
that solubility in dilute acid provides a screening method for assessing iron fortification compounds.
However, pH 1.2 is non-physiological because it is lower than the pH found within the stomach. In our
experiments, we observed that the supernatant iron concentration from NP-FePO4 at pH 1 was equal
to that of FAC, and that there was a positive correlation with Caco-2 cell ferritin concentration; iron
uptake of NP-FePO4 (200) was equal to that of FAC at pH 1. These results indicate that the dissolution
of nano-particulate iron is a function of gastric pH.
We investigated the role of DMT1 transport in iron uptake from digested NP-FePO4 in Caco-2
cells. Two to 4-fold increases in ferritin formation were observed when AA was added to the gastric
digest with NP-FePO4, similar to FAC. AA is a potent enhancer of non-heme iron absorption which
occurs via reduction of Fe3+ to Fe2+ and solubility at intestinal pH [10,47]. Our data suggest that
AA increases iron uptake of NP-FePO4, similar to FAC and FAC + AA in Caco-2 cells, by facilitating
Fe2+ DMT1 mediated uptake. We further confirmed that iron uptake from NP-FePO4 occurred via
DMT1 by incubating Caco-2 cells with 2.5 mM CaCl2. Calcium has been shown to inhibit non-heme
iron uptake in Caco-2 cells by decreasing apical protein expression of DMT1 [20]. Iron uptake from
in vitro digested FAC and NP-FePO4 was reduced when incubated with CaCl2, providing evidence
that DMT1 is required for iron uptake. Using siRNA to target DMT1 in both Caco-2 and Hutu-80 cell
lines demonstrated that iron uptake was decreased in DMT1 knockdown cells compared to control
cells in both cell lines, thereby confirming the role of DMT1 in iron uptake from NP-FePO4.
DMT1 transport is most likely the predominant mechanism of iron uptake. We also speculated
that an alternative route of iron uptake is also operational, given that ~15% of the particles were
between 50 and 400 nm (Figure 2F). Gastric pH in rats is considerably higher than pH 1 [48,49] and
our experiments showed that a large amount of iron (25%–50%) from NP-FePO4 remained insoluble
at pH 2, with little iron in the supernatant fraction at pH 4. This suggests that a significant fraction
of iron bound to NP-FePO4 could be directly transported into the epithelium by endocytosis, given
particle translocation of 200 and 500 nm particles seen in Caco-2 cells co-cultured with M-cell like
phenotype [36,50]. This was investigated using sonicated NP-FePO4. The particle size range of
sonicated NP-FePO4 (200) was similar to the range expected for the non-agglomerated fraction of
in vitro digested NP-FePO4 (200). Iron uptake from sonicated NP-FePO4 (200) was inhibited with
chlorpromazine and sucrose, and to a lesser extent DMA (Figure 5). The chemical inhibitors used
have been shown to be successful in inhibiting endocytic pathways in Caco-2 cells [24–26]. We did
not observe an effect on iron uptake from sonicated NP-FePO4 with CaCl2, suggesting that uptake
is independent of DMT1. This needs to be further clarified as excess calcium may cause particle
agglomeration. Sonicated NP-FePO4 (200) had a wide particle distribution (150–500 nm), therefore we
hypothesize that the smaller particles may be absorbed using clathrin-mediated endocytosis and the
larger particles using macropinocytosis. In recent reports, TEM micrographs of nanoparticle uptake
have been observed for iron compounds from 10–100 nm size in Caco-2 cells [26,51,52]. Moreover,
in support of our findings, a number of previous studies have shown that nano-sized iron compounds
are absorbed using endocytic pathways in Caco-2 cells [22,23,26]. This suggests that our data are not
the result of increased transcytosis of NP-FePO4 (200) caused by toxic effects induced by iron treatment
or chemical inhibitors (Supplementary Figure S2).
The long-term exposure and potential toxicity to NP-FePO4 require further investigation. Health
concerns have been raised about the toxicological effects of daily consumption of nanoparticles found
in various consumer products (see review by Nel et al. [35]). Although evidence from our study
suggests that NP-FePO4 is non-toxic to Caco-2 cells after 24 h exposure, recent studies have shown that
chronic exposure of polystyrene or TiO2 nanoparticles to Caco-2/HT-29 MTX co-cultures markedly
remodel the intestinal epithelium and affect iron absorption [53,54].
The future use of NP-FePO4 as an iron fortificant is to some extent dependent on factors other
than nutritional considerations. Food fortification for large-scale populations requires that the iron
compound is cost-effective and scalable. Although inherent disadvantages exist in the use of FeSO4
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as a fortificant, namely its rancidity/instability during storage and color induced changes to the
matrix [5,7], its use meets the criteria described above compared to other iron compounds, such as
NaFeEDTA and FePP [55]. Advances in nanotechnology necessitate decreasing the cost and increasing
the scalability of production prior to its use as an iron fortificant.
5. Conclusions
Our experiments demonstrate that iron uptake from NP-FePO4 occurred predominately through
increased iron in the supernatant fraction and entry via the DMT1 transporter in the Caco-2 cell
model. Some NP-FePO4 (200) may be absorbed intact in Caco-2 cells independently from DMT1,
but most likely this mechanism has a minor role in iron uptake. We reach this conclusion because
our digestion experiments showed less than 15% of NP-FePO4 (200) remained as particles <400 nm,
and in our sonicated NP-FePO4 (200) experiments, chlorpromazine and siRNA DMT1 treated cells
inhibited 20% of iron uptake. Our results suggest that NP-FePO4 (200) endocytosis in Caco-2 cells is
dependent on particle size, with clathrin-mediated endocytosis (CME) as the predominant mechanism
of particle internalization. To our knowledge, this is the first paper suggesting a mechanism of particle
transcytosis of iron compounds for food fortification. However, one of the assumptions made in our
experiments is that sonicated particles are similar to the nanoparticle fractions after in vitro digestion,
which illustrates the difficulties in translating the relatively novel field of nanotechnology to biological
systems. Nevertheless, our experiments suggest that the iron uptake from NP-FePO4 (200) results
from both DMT1 transport and particle transcytosis, which should be taken into consideration when
assessing the potential of iron nanoparticles for food fortification.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/4/359/s1,
Figure S1: Supernatant iron of digested NP-FePO4 after in vitro simulated GI digestion, Figure S2: Cell viability
of Caco-2 cells measured 4 h or 24 h after incubation with chemical inhibitors or iron compounds.
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